Curileum
London, GB · 1 known investors
Curileum is a biotech company developing small-molecule therapies to restore gastrointestinal tissue health, with a lead first-in-class drug (ULI262) aimed at preventing bowel cancer by redirecting precancerous polyp-forming cells and treating inflammatory bowel disease. It targets patients with familial adenomatous polyposis (FAP) and other GI diseases, with a first-in-human clinical study planned for 2027.